<DOC>
	<DOC>NCT00675844</DOC>
	<brief_summary>Extension study for subjects currently participating in protocols ACH443-015 and ACH443-018.</brief_summary>
	<brief_title>An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment</brief_title>
	<detailed_description>HIV-1-infected, clinically stable, treatment-na√Øve adults who have completed 96-weeks of elvucitabine therapy in protocol ACH443-015 and whose HIV RNA levels remain below 50 copies/mL from the 92-week assessment in protocol ACH443-015 or subjects who have completed 48-weeks of elvucitabine therapy in protocol ACH443-018 and continue to maintain a HIV-1 RNA viral load below their baseline level upon entry into protocol ACH443-018</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Subject must have successfully completed 96 weeks of elvucitabine therapy in Protocol ACH443015 OR subjects have completed 48weeks of elvucitabine therapy in protocol ACH443014A / 018. Subject has experienced viroligic rebound as defined in section 5.6.1.3 of protocol ACH443015. Subject has exceeded their baseline HIV1 RNA level by Week 44 as measured in protocol ACH443014A / 018 Subject is experiencing a drugrelated Grade 3 or 4 rash or a drug related grade 3 or 4 laboratory toxicity other than Grade 3 or 4 cholesterol, triglyceride,creatinine kinase, or LDH.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Extension study</keyword>
	<keyword>HIV-1 infection</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>